Promising clinical responses have even been seen in heavily pretreated patients, suggesting that the new therapeutic options benefit those who have exhausted all traditional lines of therapy.

The number of treatment options for both transplant eligible and transplant ineligible patients continues to grow year after year.  Regimens previously approved in the second-line setting are proving to be efficacious as primary therapy.

Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.

Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options.

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

Join Richard L. Fong, PharmD, BCOP from UCSF Helen Diller Family Comprehensive Cancer Center for this webinar in the 2018 NCCN Pharmacy Update Webinar Series on the topic Integrating New Treatment Options for Multiple Myeloma: Focus on Oral Therapies.

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive care, and follow-up for patients with myeloma.